Mologen AG (MOLGF.PK) And MEBO: Joining Forces To Treat Cancer
10/19/2005 5:11:04 PM
MOLOGEN AG and MEBO International Group, a Chinese pharmaceutical corporation, signed a cooperation agreement. The agreement was signed by Professor Xu, president of MEBO and by MOLOGEN CEO Professor Wittig during a further business trip to Beijing and Guanzhou. By combining their respective technologies MEBO and MOLOGEN will jointly develop innovative combination treatment against cancer (CoCaT). The efficacy of combined cancer treatment will be evaluated through a clinical try in China. Mologen will contribute their 4-fold gene-modified and immunomodulated tumor cells. MEBO will provide pharmaceutically processed plant (herbal extracts), which induced the differentiation of tumor cells and inhibit metastases formation. CoCaT, for the very first time, combines "western" DNA and cell technology with "far-eastern" therapeutic approaches, having their origins in traditional Chinese medicines. Scientists and Business Developers of both companies hope that CoCaT will add to the therapeutic success in clinical trials, in comparison to either therapy supplied separately. MEBO and Mologen will jointly file for patents, if the cooperation deals new intellectual property. The partnership is intended to complement and benefit both partners in their scientific and business progress.
comments powered by